Marinomed Biotech AG Reports Significant Growth in H1 2025

Marinomed Biotech AG has announced its results for the first half of 2025, revealing substantial growth in both revenue and earnings. The Austrian biotech firm reported revenues amounting to EUR 7.2 million, a stark improvement from EUR 2.4 million in the same period last year. The EBIT reached EUR 21.0 million, notably affected by a restructuring gain contributing to other operating income of EUR 19.3 million.

The company's financial position strengthened, partly due to the sale of its Carragelose business. Cash and cash equivalents rose to EUR 1.5 million as of June 30, 2025. Despite negative cash flow from operating activities at EUR –0.2 million, the firm believes the capital measures it has taken enhance its strategic negotiations and development progress.

The launch of a convertible bond worth EUR 2.5 million and a capital increase of EUR 1.1 million aims to bolster negotiations with potential partners for products like Budesolv and Tacrosolv. CEO Andreas Grassauer emphasized no further capital measures are anticipated in the current financial plans.